Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 2005

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Combined oral contraceptives in women with systemic lupus erythematosus.

AUTHORS

Petri M; Kim MY; Kalunian KC; Grossman J; Hahn BH

SOURCE

New England Journal of Medicine. 2005 Dec 15;353(24):2550-2558.

ABSTRACT

Oral contraceptives are rarely prescribed for women with systemic lupus erythematosus, because of concern about

potential negative side effects. In this double-blind, randomized, noninferiority trial, we prospectively evaluated the

effect of oral contraceptives on lupus activity in premenopausal women with systemic lupus erythematosus. A total of

183 women with inactive (76 percent) or stable active (24 percent) systemic lupus erythematosus at 15 U.S. sites

were randomly assigned to receive either oral contraceptives (triphasic ethinyl estradiol at a dose of 35 µg plus

norethindrone at a dose of 0.5 to 1 mg for 12 cycles of 28 days each; 91 women) or placebo (92 women) and were

evaluated at months 1, 2, 3, 6, 9, and 12. Subjects were excluded if they had moderate or high levels of

anticardiolipin antibodies, lupus anticoagulant, or a history of thrombosis. The primary end point, a severe lupus

flare, occurred in 7 of 91 subjects receiving oral contraceptives (7.7 percent) as compared with 7 of 92 subjects

receiving placebo (7.6 percent). The 12-month rates of severe flare were similar: 0.084 for the group receiving oral

contraceptives and 0.087 for the placebo group (P=0.95; upper limit of the one-sided 95 percent confidence interval

for this difference, 0.069, which is within the prespecified 9 percent margin for noninferiority). Rates of mild or

moderate flares were 1.40 flares per person-year for subjects receiving oral contraceptives and 1.44 flares per person-

year for subjects receiving placebo (relative risk, 0.98; P=0.86). In the group that was randomized to receive oral

contraceptives, there was one deep venous thrombosis and one clotted graft; in the placebo group, there was one

deep venous thrombosis, one ocular thrombosis, one superficial thrombophlebitis, and one death (after cessation of

the trial). Our study indicates that oral contraceptives do not increase the risk of flare among women with systemic

lupus erythematosus whose disease is stable. (PubHealth.info Document ID: CONT1T 83-06)

PubHealth.info NOTE: The author(s) of this article titled, "Combined oral contraceptives in women with systemic

lupus erythematosus.", is(are) Petri M; Kim MY; Kalunian KC; Grossman J; Hahn BH. The source of this article is

"New England Journal of Medicine. 2005 Dec 15;353(24):2550-2558.". This article was published in 2005 in English

language(s). (PubHealth.info® Document ID: CONT1T 83-06. All rights reserved with PubHealth.info) PIN: 83

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.